Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:56:29.703Z.
Calculation as of: 2026-10-06T14:56:29.703Z.
Quote observation: 2026-10-06T14:55:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a08bb0e768e445b647833b1fa03ab76594e1458f06569fc43a1aa259a4caca38
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-08-14.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Contineum Therapeutics, Inc.
Market Cap
$471.77M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$473.97M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$450.87M
EV/Sales Ratio
N/A
TTM Avg
60.56x
3Y Avg
66.18x
5Y Avg
66.18x
Market Cap
$494.46M
EV/Sales Ratio
1631.02x
TTM Avg
1857.31x
3Y Avg
1997.04x
5Y Avg
1831.19x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | $471.77M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $473.91M | 1.22x | 2.81x | 8.85x | 26.12x |
| Bright Minds Biosciences Inc. (DRUG)vs › | $473.97M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $469.55M | 2.38x | 2.48x | 2.38x | 3.66x |
| NRC Health (NRC)vs › | $461.78M | 3.92x | 3.44x | 4.04x | 5.15x |
| Evolus, Inc. (EOLS)vs › | $482.72M | 1.90x | 1.75x | 2.81x | 3.25x |
| Kamada Ltd. (KMDA)vs › | $459.82M | 2.30x | 2.30x | 1.99x | 1.91x |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $450.87M | N/A | 60.56x | 66.18x | 66.18x |
| Oculis Holding AG (OCS)vs › | $494.46M | 1631.02x | 1857.31x | 1997.04x | 1831.19x |
| Capricor Therapeutics, Inc. (CAPR)vs › | $446.57M | N/A | 45.86x | 24.99x | 87.94x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2024-08-14 | 12.43x |
| 2024-08-13 | 11.91x |
| 2024-08-12 | 12.45x |
| 2024-08-09 | 11.93x |
| 2024-08-08 | 12.08x |
| 2024-08-07 | 12.21x |
| 2024-08-06 | 12.88x |
| 2024-08-05 | 12.23x |
| 2024-08-02 | 13.19x |
| 2024-08-01 | 13.57x |
| 2024-07-31 | 13.86x |
| 2024-07-30 | 14.44x |
| 2024-07-29 | 14.44x |
| 2024-07-26 | 14.34x |
| 2024-07-25 | 14.37x |
| 2024-07-24 | 14.38x |
| 2024-07-23 | 14.59x |
| 2024-07-22 | 14.54x |
| 2024-07-19 | 13.91x |
| 2024-07-18 | 14.36x |
| 2024-07-17 | 14.37x |
| 2024-07-16 | 14.73x |
| 2024-07-15 | 14.34x |
| 2024-07-12 | 14.22x |
| 2024-07-11 | 14.34x |
| 2024-07-10 | 14.37x |
| 2024-07-09 | 14.15x |
| 2024-07-08 | 14.29x |
| 2024-07-05 | 13.84x |
| 2024-07-03 | 13.87x |
| 2024-07-02 | 14.18x |
| 2024-07-01 | 14.34x |
| 2024-06-28 | 12.60x |
| 2024-06-27 | 13.19x |
| 2024-06-26 | 14.24x |
| 2024-06-25 | 13.79x |
| 2024-06-24 | 13.41x |
| 2024-06-21 | 13.10x |
| 2024-06-20 | 13.66x |
| 2024-06-18 | 13.34x |
| 2024-06-17 | 11.77x |
| 2024-06-14 | 11.77x |
| 2024-06-13 | 12.07x |
| 2024-06-12 | 12.11x |
| 2024-06-11 | 11.74x |
| 2024-06-10 | 12.76x |
| 2024-06-07 | 11.93x |
| 2024-06-06 | 11.83x |
| 2024-06-05 | 11.82x |
| 2024-06-04 | 11.63x |
| 2024-06-03 | 11.63x |
| 2024-05-31 | 11.42x |
| 2024-05-30 | 11.26x |
| 2024-05-29 | 11.44x |
| 2024-05-28 | 11.10x |
| 2024-05-24 | 11.65x |
| 2024-05-23 | 11.83x |
| 2024-05-22 | 11.70x |
| 2024-05-21 | 11.77x |
| 2024-05-20 | 11.62x |
| 2024-05-17 | 11.51x |
| 2024-05-16 | 11.07x |
| 2024-05-15 | 11.25x |
| 2024-05-14 | 11.32x |
| 2024-05-13 | 11.33x |
| 2024-05-10 | 11.50x |
| 2024-05-09 | 11.61x |
| 2024-05-08 | 11.44x |
| 2024-05-07 | 11.00x |
| 2024-05-06 | 11.00x |
| 2024-05-03 | 10.64x |
| 2024-05-02 | 11.04x |
| 2024-05-01 | 11.32x |
| 2024-04-30 | 11.39x |
| 2024-04-29 | 11.60x |
| 2024-04-26 | 11.45x |
| 2024-04-25 | 11.59x |
| 2024-04-24 | 11.56x |
| 2024-04-23 | 11.55x |
| 2024-04-22 | 11.46x |
| 2024-04-19 | 11.30x |
| 2024-04-18 | 11.33x |
| 2024-04-17 | 11.29x |
| 2024-04-16 | 11.37x |
| 2024-04-15 | 10.90x |
| 2024-04-12 | 11.34x |
| 2024-04-11 | 11.55x |
| 2024-04-10 | 10.97x |
| 2024-04-09 | 11.20x |
| 2024-04-08 | 11.22x |
| 2024-04-05 | 11.29x |
